CD274 and neoplasm: In 2019, atezolizumab, an anti-PD-L1 monoclonal antibody, was approved in combination with nab-paclitaxel chemotherapy as first-line treatment of patients with locally advanced or metastatic TNBC whose tumours were positive for PD-L1 expression (≥1%) in immune infiltrate, and the Ventana PD-L1 (SP142) antibody had been approved as the complementary diagnostics by the Food and Drug Administration in the United States [107].